Results 21 to 30 of about 64,512 (289)

The molecular dynamics of MDM2 [PDF]

Cell Cycle, 2010
The pro-oncogenic signals of a vast number of anti-cancer drug targets are mediated by protein-protein interactions. This has made such targets less attractive to classic drug discovery programmes. New paradigms in the protein science field have revealed, however, that many protein-protein complexes are stabilized by an interaction between an ...
Judith, Nicholson, Ted R, Hupp
openaire   +2 more sources

Mdm2: Open questions [PDF]

Cancer Science, 2020
AbstractThe Mdm2 oncoprotein and its association with p53 were discovered 30 years ago, and a cornucopia of activities and regulatory pathways have been associated with it. In this review, we will raise questions about Mdm2 and its cousin Mdm4 that we consider worth pursuing in future research, reaching from molecular structures and intracellular ...
Matthias Dobbelstein, Arnold J. Levine
openaire   +3 more sources

HDAC2 links ubiquitination to tumor suppression in synovial sarcoma

Molecular & Cellular Oncology, 2021
The function of histone deacetylase 2 (HDAC2) in transcriptional regulation and its role in oncogenesis have been well established. Here we discuss a transcription-independent HDAC2 pathway controlling cancer-related protein stability via the mouse ...
Christina Cooley, Le Su
doaj   +1 more source

MAGE-A cancer/testis antigens inhibit MDM2 ubiquitylation function and promote increased levels of MDM4 [PDF]

, 2015
Melanoma antigen A (MAGE-A) proteins comprise a structurally and biochemically similar sub-family of Cancer/Testis antigens that are expressed in many cancer types and are thought to contribute actively to malignancy.
Susan E. Bray (264528), Thompson, Alastair M., Hourihan John, Quinlan Philip R., Philip R. Quinlan (743773), Thompson Alastair M., Meek, David W., Alastair M. Thompson (743775), Meek, David W, Marcar Lynnette, Lee B. Jordan (743774), Ihrig Bianca, David W Meek, Ted R. Hupp (141798), Hupp Ted R., Ihrig, Bianca, Hourihan, John, Meek David W., Bray Susan E., Thompson, Alastair M, Quinlan, Philip R., Susan E Bray, Lynnette Marcar (743770), Hupp, Ted R., John Hourihan, Philip R Quinlan, Jordan, Lee B., Bray, Susan E, Ted R Hupp, Lynnette Marcar, Quinlan, Philip R, David W. Meek (743776), Jordan Lee B., Alastair M Thompson, Marcar, Lynnette, Bianca Ihrig, John Hourihan (743772), Hupp, Ted R, Bray, Susan E., Lee B Jordan, Bianca Ihrig (743771), Jordan, Lee B   +41 more
core   +2 more sources

MDM2 negatively regulates the human telomerase RNA gene promoter [PDF]

, 2005
<b>Background:</b> We have previously demonstrated that NF-Y and Sp1 interact with the human telomerase RNA (hTR) promoter and play a central role in its regulation. We have also shown that pRB activates the hTR promoter, but the mechanism
Jiangqin Zhao (6471), Keith, W.N., Katrina Jackson (6473), Bilsland, A., Jackson, K., Keith W Nicol, Alan Bilsland (6472), Zhao, J., Zhao Jiangqin, Bilsland Alan, Jackson Katrina, W. Nicol Keith (261494), Alan Bilsland, Katrina Jackson, Jiangqin Zhao, W Nicol Keith   +15 more
core   +2 more sources

The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a. [PDF]

, 2014
p53 and its major E3 ligase Mdm2 are both ubiquitinated and targeted to the proteasome for degradation. Despite the importance of this in regulating the p53 pathway, little is known about the mechanisms of proteasomal recognition of ubiquitinated p53 and
J Das, S Menendez, Menendez, S., Saville, M. K., S Dayal, Das, J., M K Saville, Dayal, S., A Sparks, Robertson, P., P Robertson, Sparks, A.   +11 more
core   +1 more source

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers [PDF]

, 2006
BackgroundThe MDM2 gene encodes a negative regulator of the p53 tumour suppressor protein. A single nucleotide polymorphism (SNP) in the MDM2 promoter (a T to G exchange at nucleotide 309) has been reported to produce accelerated tumour formation in ...
Johnson, Peter W., White Helen E, Jeremy P Blaydes, Diana M Eccles, White, Helen E., Ellen R Copson, Johnson Peter W, Eccles Diana M, Eccles, Diana M., Helen E White, Robinson, David O., David O Robinson, Peter W Johnson, Blaydes, Jeremy P., Copson, Ellen R., Robinson David O, Copson Ellen R, Blaydes Jeremy P   +17 more
core   +2 more sources

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation. [PDF]

, 2011
BACKGROUND: The mammalian DNA-damage response (DDR) has evolved to protect genome stability and maximize cell survival following DNA-damage. One of the key regulators of the DDR is p53, itself tightly regulated by MDM2. Following double-strand DNA breaks
Valentine, Jane M., Kumar Sonia, Abdeladim Moumen, Moumen, Abdeladim, Valentine Jane M, Jane M Valentine, Moumen Abdeladim, Sonia Kumar, Kumar, Sonia, Kumar, S, Moumen, A, Valentine, JM   +11 more
core   +2 more sources

The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma [PDF]

Head and Neck Pathology, 2020
Craniofacial osteosarcoma is rare (2-10% of all osteosarcomas). Most low grade fibroblastic osteosarcomas of the long bones are characterized by amplification of chromosome12q including MDM2 and CDK4 genes. This study aims to investigate the utility of MDM2 and CDK4 immunostains as well as MDM2 FISH in craniofacial osteosarcomas as a means of ...
Abberly Lott Limbach, Mark W. Lingen, James McElherne, Heather Mashek, Carrie Fitzpatrick, Elizabeth Hyjek, Reza Mostofi, Nicole A. Cipriani   +7 more
openaire   +2 more sources

Methoxyphenyl Imidazolines as Potential Activators of p53

Medical Sciences Forum, 2022
The use of p53-MDM2/X inhibitors is a prospective strategy in anti-cancer therapy for tumors with wild type p53 protein. In our study, new low-molecular-weight inhibitors of the p53-mdm2 interaction have been proposed.
Daniil R. Bazanov, Nikolay V. Pervushin, Natalia A. Lozinskaya, Gelina S. Kopeina   +3 more
doaj   +1 more source